Komori
Governance4506Sumitomo Pharma Co.,Ltd.Pharmaceuticals

Corporate Governance Report 2027/07/01

The report includes diagrams illustrating the organizational structure of a company with an Audit and Supervisory Committee, as well as the establishment of committees including the Nomination and Compensation Committee and the Committee for Oversight of Conflicts of Interest in Transactions Between Group Companies. However, it does not describe any changes from the previous report.

Worth reading
64In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Committee5
Nomination and Compensation CommitteeCommittee for Oversight of Conflicts of Interest in Transactions Between Group CompaniesCompliance CommitteeQuality and Safety Committeeand Information Management Committee. The proportion of outside committee members is 非開示
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeNomination and Compensation Committee, Committee for Oversight of Conflicts of Interest in Transactions Between Group Companies, Compliance Committee, Quality and Safety Committee, and Information Management Committee. The proportion of outside committee members is Not disclosed
Items this document does not state (6)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The reasons for the changes from the previous report are not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2027/07/01 | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure | Komori